Using ICH GCP and the recent FDA guidance for clinical trials impacted by COVID-

Using ICH GCP and the recent FDA guidance for clinical trials impacted by COVID-19, please identify and describe three responsibilities of monitoring that would be impacted by a pause in on-site monitoring visits due to the COVID-19 pandemic.